917878-65-0

Usage

Uses

Used in Pharmaceutical Synthesis:
7-BROMO-3-CHLORO-5H-BENZO[4,5]CYCLOHEPTA[1,2-B]PYRIDIN-5-ONE is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with specific biological activities, targeting a range of therapeutic areas.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 7-BROMO-3-CHLORO-5H-BENZO[4,5]CYCLOHEPTA[1,2-B]PYRIDIN-5-ONE is utilized as a starting material for the exploration of novel chemical entities. Its potential pharmacological properties are of interest for the creation of innovative therapeutic agents.
Used in Organic Material Synthesis:
Beyond pharmaceutical applications, 7-BROMO-3-CHLORO-5H-BENZO[4,5]CYCLOHEPTA[1,2-B]PYRIDIN-5-ONE is also employed in the synthesis of other organic materials. Its complex ring system provides a foundation for the development of materials with specialized chemical properties.
It is crucial to handle 7-BROMO-3-CHLORO-5H-BENZO[4,5]CYCLOHEPTA[1,2-B]PYRIDIN-5-ONE with care, adhering to safety guidelines to mitigate any potential hazards associated with its use in research and development.

InChI:InChI=1/C14H7BrClNO/c15-9-3-1-8-2-4-13-12(6-10(16)7-17-13)14(18)11(8)5-9/h1-7H

Upstream product

• 917882-51-0 2-[(E/Z)-2-(4-bromophenyl)vinyl]-3-carboxy-5-chloropyridinium chloride 
• 1170702-73-4 2-[(E)-2-(4-bromophenyl)vinyl]-5-chloronicotinic acid 
• 350597-49-8 2-methyl-5-chloro methylnicotinate 
• 917942-73-5 C₁₄H₉BrClNO₂ 
• 1122-91-4 4-bromo-benzaldehyde 

Downstream Products

• 917878-68-3 3-chloro-7-[(2,4-dimethoxybenzyl)amino]-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 
• 917882-66-7 MK-2461 
• 1309960-89-1 N-(3-chloro-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl)-N-(2,4-dimethoxybenzyl)ethenesulfonamide 
• 1309960-90-4 N-(3-chloro-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl)-N-(2,4-dimethoxybenzyl)-2-(1H-imidazol-1-yl)ethanesulfonamide 
• 1309960-77-7 N-methyl-N'-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyrazin-2-ylmethyl)sulfuric diamide 
• 917882-66-7 N-((2R)-1,4-dioxan-2-ylmethyl)-N-methyl-N’-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]sulfamide 
• 1427584-55-1 3-chloro-7-(hydroxymethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 
• 1427584-36-8 C₂₆H₂₀N₄O₂ 
• 1427584-37-9 C₂₇H₂₂N₄O₂ 
• 1001915-86-1 1-(3-chloro-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl)-N-methyl-N-phenylmethanesulfonamide 
• 1001915-85-0 methyl (3-chloro-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]-pyridin-7-yl)[methyl(phenyl)sulfamoyl]acetate 

Relevant academic research and scientific papers

Process development and large-scale synthesis of a c-Met kinase inhibitor

A highly convergent synthesis of c-Met kinase inhibitor 1 has been demonstrated on a multikilogram scale using three key fragments: dihalotricyclic core 2, chiral sulfamide side chain 3, and pyrazole boronic ester 4. The chirality in sulfamide side chain 3 was installed using the cheap and readily available starting material (S)-epichlorohydrin. A total of 2.71 kg of 1 were isolated in seven steps (the longest linear sequence).

Discovery of a 5 H-benzo[4,5]cyclohepta[1,2-b ]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer

c-Met is a transmembrane tyrosine kinase that mediates activation of several signaling pathways implicated in aggressive cancer phenotypes. In recent years, research into this area has highlighted c-Met as an attractive cancer drug target, triggering a number of approaches to disrupt aberrant c-Met signaling. Screening efforts identified a unique class of 5H-benzo[4,5] cyclohepta[1,2-b]pyridin-5-one kinase inhibitors, exemplified by 1. Subsequent SAR studies led to the development of 81 (MK-2461), a potent inhibitor of c-Met that was efficacious in preclinical animal models of tumor suppression. In addition, biochemical studies and X-ray analysis have revealed that this unique class of kinase inhibitors binds preferentially to the activated (phosphorylated) form of the kinase. This report details the development of 81 and provides a description of its unique biochemical properties.

Tyrosine kinase inhibitors

This invention relates to salt forms of the compound N-[(2R)-1,4-dioxan-2-ylmethyl]-N-methyl-N′-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]sulfamide, an inhibitor of tyrosine kinases, in particular the receptor tyrosine

Tyrosine kinase inhibitors

The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

TYROSINE KINASE INHIBITORS

The present invention relates to pyrido[3,2-c]benzazocinone derivatives and related compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kina